These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32220959)

  • 21. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
    Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
    Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allosteric interactions prime androgen receptor dimerization and activation.
    Wasmuth EV; Broeck AV; LaClair JR; Hoover EA; Lawrence KE; Paknejad N; Pappas K; Matthies D; Wang B; Feng W; Watson PA; Zinder JC; Karthaus WR; de la Cruz MJ; Hite RK; Manova-Todorova K; Yu Z; Weintraub ST; Klinge S; Sawyers CL
    Mol Cell; 2022 Jun; 82(11):2021-2031.e5. PubMed ID: 35447082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
    Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
    J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ELF3 is a repressor of androgen receptor action in prostate cancer cells.
    Shatnawi A; Norris JD; Chaveroux C; Jasper JS; Sherk AB; McDonnell DP; Giguère V
    Oncogene; 2014 Feb; 33(7):862-71. PubMed ID: 23435425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells.
    Zhang Z; Chng KR; Lingadahalli S; Chen Z; Liu MH; Do HH; Cai S; Rinaldi N; Poh HM; Li G; Sung YY; Heng CL; Core LJ; Tan SK; Ruan X; Lis JT; Kellis M; Ruan Y; Sung WK; Cheung E
    Genome Res; 2019 Feb; 29(2):223-235. PubMed ID: 30606742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
    Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
    J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
    Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
    Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
    Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
    J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.
    Madison BJ; Clark KA; Bhachech N; Hollenhorst PC; Graves BJ; Currie SL
    J Biol Chem; 2018 Nov; 293(48):18624-18635. PubMed ID: 30315111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.
    Li F; Yuan Q; Di W; Xia X; Liu Z; Mao N; Li L; Li C; He J; Li Y; Guo W; Zhang X; Zhu Y; Aji R; Wang S; Tong X; Ji H; Chi P; Carver B; Wang Y; Chen Y; Gao D
    J Clin Invest; 2020 Nov; 130(11):5924-5941. PubMed ID: 32701507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
    Mao N; Gao D; Hu W; Hieronymus H; Wang S; Lee YS; Lee C; Choi D; Gopalan A; Chen Y; Carver BS
    Mol Cancer Ther; 2019 Sep; 18(9):1577-1586. PubMed ID: 31296553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
    Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
    J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
    Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
    Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
    Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors.
    Currie SL; Warner SL; Vankayalapati H; Liu X; Sharma S; Bearss DJ; Graves BJ
    SLAS Discov; 2019 Jan; 24(1):77-85. PubMed ID: 30204534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.